PDCD1 and triple-negative breast carcinoma: Assessments of the PD-1/PD-L1 pathway are today used as biomarkers for immunotherapy in metastatic triple-negative breast cancer.38 Expression is associated with an improved prognosis,39 despite the inherent immunosuppressive effects, likely due to its association with an active immune response.